<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40803668</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2233-6087</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Diabetes &amp; metabolism journal</Title><ISOAbbreviation>Diabetes Metab J</ISOAbbreviation></Journal><ArticleTitle>Comparison of Efficacy and Safety of Cilostazol/Extract of Ginkgo biloba vs. Aspirin in Carotid Atherosclerosis in Patients with Diabetes Mellitus.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4093/dmj.2025.0146</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">We conducted a prospective, randomized study to evaluate the combination of cilostazol (CTZ) and extract of Ginkgo biloba (EGb) and compare it with aspirin for the prevention of atherosclerosis progression in patients with type 2 diabetes mellitus (T2DM).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">One hundred five patients with T2DM and increased carotid intima-media thickness (IMT) were randomly assigned to receive either CTZ 200 mg plus EGb 160 mg once daily or aspirin (ASA) 100 mg/day for 12 months. The primary endpoint was the change in maximum carotid IMT.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The mean age and body mass index were 61.6&#xb1;8.4 years and 25.2&#xb1;3.1 kg/m2 in the CTZ/EGb group and 61.6&#xb1;7.6 years and 24.5&#xb1;3.3 kg/m2 in the ASA group, respectively. CTZ/EGb treatment reduced the maximum IMT in the bulb area (from 1.435&#xb1;0.690 to 1.346&#xb1;0.688 mm on the right; from 1.359&#xb1;0.528 to 1.299&#xb1;0.528 mm on the left), whereas ASA treatment did not, resulting in significant between-group differences (P&lt;0.05). No significant differences were observed in the common carotid and internal carotid arteries. The CTZ/EGb group showed a reduction in triglycerides and an increase in high-density lipoprotein cholesterol levels. Additionally, aspartate and alanine aminotransferase levels decreased only in the CTZ/EGb group. There were no significant differences in Mini-Mental State Examination (MMSE) score changes or adverse events (ClinicalTrials.gov number: NCT05906199).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Twelve months of CTZ/EGb combination therapy significantly attenuated the progression of carotid atherosclerosis compared with aspirin in patients with T2DM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>You-Cheol</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Mi Kyung</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jung Hwan</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Han Mi</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Physiologic Diagnostic Laboratory, Vascular Laboratory, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sang Yong</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chosun University Hospital, Chosun University College of Medicine, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Soo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05906199</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Diabetes Metab J</MedlineTA><NlmUniqueID>101556588</NlmUniqueID><ISSNLinking>2233-6079</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aspirin</Keyword><Keyword MajorTopicYN="N">Atherosclerosis</Keyword><Keyword MajorTopicYN="N">Carotid artery diseases</Keyword><Keyword MajorTopicYN="N">Cilostazol</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus, type 2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>14</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>14</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>13</Day><Hour>19</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40803668</ArticleId><ArticleId IdType="doi">10.4093/dmj.2025.0146</ArticleId><ArticleId IdType="pii">dmj.2025.0146</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>